Apellis Pharmaceuticals (APLS) Receives a Buy from Oppenheimer


Oppenheimer analyst Justin Kim assigned a Buy rating to Apellis Pharmaceuticals (APLS) yesterday and set a price target of $62.00. The company’s shares closed last Thursday at $44.90.

According to TipRanks.com, Kim is a 5-star analyst with an average return of 43.0% and a 82.1% success rate. Kim covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, Aldeyra Therapeutics, and Chinook Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apellis Pharmaceuticals with a $67.90 average price target.

See today’s analyst top recommended stocks >>

Based on Apellis Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $646K and GAAP net loss of $136 million. In comparison, last year the company had a GAAP net loss of $69.83 million.

Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APLS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts